Published in Blood on April 17, 2007
Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell (2012) 5.44
Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol (2011) 4.34
Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood (2009) 2.36
Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group. Pediatr Blood Cancer (2011) 1.32
Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. J Clin Oncol (2012) 1.30
Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity. Hematol Oncol (2009) 1.29
Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood (2010) 1.16
Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients: a report from the Children's Oncology Group. Cancer (2013) 1.14
Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. Blood (2012) 1.10
Children's Oncology Group's 2013 blueprint for research: acute myeloid leukemia. Pediatr Blood Cancer (2012) 1.08
Childhood acute myeloid leukaemia. Br J Haematol (2012) 1.04
Progress of minimal residual disease studies in childhood acute leukemia. Curr Hematol Malig Rep (2010) 1.02
Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. J Clin Oncol (2015) 1.00
Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML. Mol Cancer Res (2013) 0.98
Prognostic significance of nucleophosmin mutations and FLT3 internal tandem duplication in adult patients with cytogenetically normal acute myeloid leukemia. Korean J Hematol (2010) 0.96
High EVI1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology group. Br J Haematol (2013) 0.93
The frequency of NPM1 mutations in childhood acute myeloid leukemia. J Hematol Oncol (2010) 0.89
Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia. J Mol Diagn (2009) 0.85
How I treat pediatric acute myeloid leukemia. Blood (2012) 0.84
Rapid method for detection of mutations in the nucleophosmin gene in acute myeloid leukemia. J Mol Diagn (2008) 0.84
NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human disease. Exp Hematol (2013) 0.84
Measurements of treatment response in childhood acute leukemia. Korean J Hematol (2012) 0.84
Molecular and alternative methods for diagnosis of acute myeloid leukemia with mutated NPM1: flexibility may help. Haematologica (2010) 0.83
High-resolution melting curve analysis, a rapid and affordable method for mutation analysis in childhood acute myeloid leukemia. Front Pediatr (2014) 0.77
Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML). Clin Lymphoma Myeloma Leuk (2016) 0.77
Minimal residual disease detection in pediatric acute myeloid leukemia: does flow cytometry score a point over molecular biology? Transl Pediatr (2013) 0.75
Accurate Medicine: Indirect Targeting of NPM1-Mutated AML. Cancer Discov (2016) 0.75
Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Clin Cancer Res (2015) 0.75
Acute myeloid leukemia in infants: biology and treatment. Front Pediatr (2015) 0.75
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med (2005) 12.18
Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science (1994) 10.45
Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood (2006) 5.43
Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell (2000) 3.91
Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood (2005) 3.90
Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol (2002) 3.67
Clinical implications of FLT3 mutations in pediatric AML. Blood (2006) 2.72
Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood (2002) 2.71
Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood (2001) 2.53
FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood (2001) 2.53
Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. Blood (2005) 2.24
Nucleolar protein B23 has molecular chaperone activities. Protein Sci (1999) 2.07
Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. Hematol J (2003) 1.85
ARF impedes NPM/B23 shuttling in an Mdm2-sensitive tumor suppressor pathway. Mol Cell Biol (2004) 1.77
Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood (2005) 1.74
Hazard rate models with covariates. Biometrics (1979) 1.69
Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood (2005) 1.66
Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia (2006) 1.60
Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. Blood (2004) 1.41
Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution. Cancer Res (2006) 1.31
Detection of normal and chimeric nucleophosmin in human cells. Blood (1999) 1.20
Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. Blood (2005) 1.14
Preribosomal ribonucleoprotein particles are a major component of a nucleolar matrix fraction. Biochemistry (1986) 1.12
Tryptophans 286 and 288 in the C-terminal region of protein B23.1 are important for its nucleolar localization. Biosci Biotechnol Biochem (2002) 1.06
Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations. Leukemia (2007) 1.05
Different types of NPM1 mutations in children and adults: evidence for an effect of patient age on the prevalence of the TCTG-tandem duplication in NPM1-exon 12. Leukemia (2006) 0.93
Environmental genotoxicants/carcinogens and childhood cancer: bridgeable gaps in scientific knowledge. Mutat Res (2006) 0.90
Aberrant subcellular expression of nucleophosmin and NPM-MLF1 fusion protein in acute myeloid leukaemia carrying t(3;5): a comparison with NPMc+ AML. Leukemia (2006) 0.90
DNA repair during organogenesis. Mutat Res (2002) 0.87
Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. PLoS One (2012) 5.28
Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol (2011) 4.34
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood (2004) 3.76
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol (2010) 3.76
Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. Blood (2007) 3.11
Abnormalities of the large ribosomal subunit protein, Rpl35a, in Diamond-Blackfan anemia. Blood (2008) 3.05
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst (2008) 2.77
Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood (2003) 2.76
A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood (2002) 2.76
Clinical implications of FLT3 mutations in pediatric AML. Blood (2006) 2.72
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood (2011) 2.66
The majority of total nuclear-encoded non-ribosomal RNA in a human cell is 'dark matter' un-annotated RNA. BMC Biol (2010) 2.59
A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. Blood (2006) 2.58
Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood (2009) 2.57
Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood (2012) 2.39
Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood (2009) 2.36
Error reduction in pediatric chemotherapy: computerized order entry and failure modes and effects analysis. Arch Pediatr Adolesc Med (2006) 2.30
Mortality in overweight and underweight children with acute myeloid leukemia. JAMA (2005) 2.25
Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. Blood (2005) 2.24
Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. Blood (2005) 2.22
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood (2006) 2.18
Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia. Blood (2012) 2.17
Misinterpretation of a Calvert-derived formula leading to carboplatin overdose in two children. J Pediatr Hematol Oncol (2003) 2.14
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood (2011) 2.14
Diagnostic potential of urinary α1-antitrypsin and apolipoprotein E in the detection of bladder cancer. J Urol (2012) 2.12
Ribosomal protein genes RPS10 and RPS26 are commonly mutated in Diamond-Blackfan anemia. Am J Hum Genet (2010) 2.05
In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood (2004) 2.03
Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891. J Clin Oncol (2003) 1.93
A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood (2008) 1.90
Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. Blood (2007) 1.89
Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations. J Exp Med (2006) 1.88
Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting. Blood (2010) 1.87
Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood (2004) 1.86
Growth retardation and premature aging phenotypes in mice with disruption of the SNF2-like gene, PASG. Genes Dev (2004) 1.84
Significant responses to platinum-based chemotherapy in renal medullary carcinoma. Pediatr Blood Cancer (2005) 1.83
Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagn (2003) 1.82
Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971. Blood (2011) 1.81
Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clin Cancer Res (2007) 1.80
Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML. Blood (2008) 1.80
Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. J Clin Oncol (2014) 1.79
Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group. Blood (2006) 1.74
Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood (2011) 1.69
Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model. Blood (2008) 1.67
FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood (2003) 1.65
Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML. Blood (2006) 1.65
Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol (2006) 1.62
Lack of KIT or FMS internal tandem duplications but co-expression with ligands in AML. Leuk Res (2004) 1.62
The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity. Blood (2007) 1.60
The presence of central nervous system disease at diagnosis in pediatric acute myeloid leukemia does not affect survival: a Children's Oncology Group study. Pediatr Blood Cancer (2010) 1.59
Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: a retrospective study. Leuk Lymphoma (2008) 1.57
Ribosomal protein gene deletions in Diamond-Blackfan anemia. Blood (2011) 1.57
The E3 ligase HACE1 is a critical chromosome 6q21 tumor suppressor involved in multiple cancers. Nat Med (2007) 1.55
DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update. Mol Cancer (2008) 1.55
Critical windows of exposure to household pesticides and risk of childhood leukemia. Environ Health Perspect (2002) 1.52
Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. Blood (2006) 1.52
A modified sign test for comparing paired ROC curves. Biostatistics (2007) 1.51
Outcomes of transplantation in children with primary hepatic malignancy. Pediatr Transplant (2007) 1.48
Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPalpha expression. Blood (2003) 1.47
Identification of genes with abnormal expression changes in acute myeloid leukemia. Genes Chromosomes Cancer (2008) 1.46
CD36 (thrombospondin receptor) expression in childhood acute megakaryoblastic leukemia: in vitro drug sensitivity and outcome. Leuk Lymphoma (2006) 1.45
End points to establish the efficacy of new agents in the treatment of acute leukemia. Blood (2006) 1.43
Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. Blood (2003) 1.43
Enteric gram-negative bacilli bloodstream infections: 17 years' experience in a neonatal intensive care unit. Am J Infect Control (2004) 1.41
Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. Blood (2004) 1.41
Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J Clin Oncol (2006) 1.40
A phase II study of amifostine in children with myelodysplastic syndrome: a report from the Children's Oncology Group study (AAML0121). Pediatr Blood Cancer (2011) 1.39
The MonoPrep Pap test for the detection of cervical cancer and its precursors. Part I: results of a multicenter clinical trial. Am J Clin Pathol (2008) 1.38
FLT3 tyrosine kinase inhibitors. Int J Hematol (2005) 1.38
Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood (2003) 1.37
FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. Blood (2003) 1.35
Central nervous system disease in Langerhans cell histiocytosis. J Pediatr (2010) 1.32